Varenicline and risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport accidents and offences: population based cohort study
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine associations between varenicline and the incidence of a range of adverse outcomes. DESIGN: Population based cohort study using within person analyses to control for confounding by indication. SETTING: Whole population of Sweden. PARTICIPANTS: 7,917,436 people aged 15 and over, of whom 69,757 were treated with varenicline between 2006 and 2009. MAIN OUTCOME MEASURES: Incidence of new psychiatric conditions, suicidal behaviour, suspected and convicted criminal offending, transport accidents, and suspected and convicted traffic offences. RESULTS: In the whole population, 337,393 new psychiatric conditions were diagnosed during follow-up. In addition, 507,823 suspected and 338,608 convicted crimes, 40,595 suicidal events, 124,445 transport accidents, and 99,895 suspected and 57,068 convicted traffic crimes were recorded. Within person analyses showed that varenicline was not associated with significant hazards of suicidal behaviour, criminal offending, transport accidents, traffic offences, or psychoses. However, varenicline was associated with a small increase in the risk of anxiety conditions (hazard ratio 1.23, 95% confidence interval 1.01 to 1.51) and mood conditions (1.31, 1.06 to 1.63), which was only seen in people with pre-existing psychiatric disorders. CONCLUSIONS: Concerns that varenicline is associated with an increased risk of many adverse outcomes, including suicidality and accidents, are not supported in this observational study. The small increase in risk of two psychiatric conditions in people with pre-existing psychiatric disorders needs to be confirmed using other research designs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
External review and validation of the Swedish national inpatient register
Ludvigsson, J. F., Andersson, E., Ekbom, A., Feychting, M., Kim, J.-L., Reuterwall, C., Heurgren, M., & Olausson, P. O. (2011) · BMC Public Health · doi:10.1186/1471-2458-11-450 · Cited by 5,055
Wettermark, B., Hammar, N., MichaelFored, C., Leimanis, A., Otterblad Olausson, P., Bergman, U., Persson, I., Sundström, A., Westerholm, B., & Rosén, M. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1294 · Cited by 1,887
Smoking prevalence and cigarette consumption in 187 countries, 1980-2012
Ng, M., Freeman, M. K., Fleming, T. D., Robinson, M., Dwyer-Lindgren, L., Thomson, B., Wollum, A., Sanman, E., Wulf, S., Lopez, A. D., et al. (2014) · JAMA · doi:10.1001/jama.2013.284692 · Cited by 1,576
Pharmacological interventions for smoking cessation: an overview and network meta-analysis
Cahill, K., Stevens, S., Perera, R., & Lancaster, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009329.pub2 · Cited by 1,243
Medication for Attention Deficit–Hyperactivity Disorder and Criminality
Lichtenstein, P., Halldner, L., Zetterqvist, J., Sjölander, A., Serlachius, E., Fazel, S., Långström, N., & Larsson, H. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203241 · Cited by 611
Self-citationCo‐Morbidity of Smoking in Patients with Psychiatric and Substance Use Disorders
Kalman, D., Morissette, S. B., & George, T. P. (2005) · The American Journal on Addictions · doi:10.1080/10550490590924728 · Cited by 594
The population impact of severe mental illness on violent crime
Fazel, S., & Grann, M. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.8.1397 · Cited by 539
Self-citationChang, Z., Lichtenstein, P., D’Onofrio, B. M., Sjölander, A., & Larsson, H. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.4174 · Cited by 293
Self-citationSmoking and suicide: A brief overview
Hughes, J. R. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.06.003 · Cited by 236
Evins, A. E., Cather, C., Pratt, S. A., Pachas, G. N., Hoeppner, S. S., Goff, D. C., Achtyes, E. D., Ayer, D., & Schoenfeld, D. A. (2014) · JAMA · doi:10.1001/jama.2013.285113 · Cited by 207
Gunnell, D., Irvine, D., Wise, L., Davies, C., & Martin, R. M. (2009) · BMJ · doi:10.1136/bmj.b3805 · Cited by 200
Chen, Q., Sjolander, A., Runeson, B., D'Onofrio, B. M., Lichtenstein, P., & Larsson, H. (2014) · BMJ · doi:10.1136/bmj.g3769 · Cited by 170
Self-citationSuicidal Behavior and Depression in Smoking Cessation Treatments
Moore, T. J., Furberg, C. D., Glenmullen, J., Maltsberger, J. T., & Singh, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027016 · Cited by 150
Tonstad, S., Davies, S., Flammer, M., Russ, C., & Hughes, J. (2010) · Drug Safety · doi:10.2165/11319180-000000000-00000 · Cited by 142
Varenicline, Smoking Cessation, and Neuropsychiatric Adverse Events
Gibbons, R. D., & Mann, J. J. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12121599 · Cited by 142
Cinciripini, P. M., Robinson, J. D., Karam-Hage, M., Minnix, J. A., Lam, C., Versace, F., Brown, V. L., Engelmann, J. M., & Wetter, D. W. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.678 · Cited by 136
Thomas, K. H., Martin, R. M., Davies, N. M., Metcalfe, C., Windmeijer, F., & Gunnell, D. (2013) · BMJ · doi:10.1136/bmj.f5704 · Cited by 119
Chengappa, K. N. R., Perkins, K. A., Brar, J. S., Schlicht, P. J., Turkin, S. R., Hetrick, M. L., Levine, M. D., & George, T. P. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08756 · Cited by 86
Harrison-Woolrych, M., & Ashton, J. (2011) · Drug Safety · doi:10.2165/11594450-000000000-00000 · Cited by 54
Neuropsychiatric Adverse Events of Varenicline: A Systematic Review of Published Reports
Ahmed, A. I. A., Ali, A. N. A., Kramers, C., Härmark, L. V. D., Burger, D. M., & Verhoeven, W. M. A. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31827c0117 · Cited by 34
Cited by
Anthenelli, R. M., Benowitz, N. L., West, R., St Aubin, L., McRae, T., Lawrence, D., Ascher, J., Russ, C., Krishen, A., & Evins, A. E. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30272-0 · Cited by 1,177
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub7 · Cited by 433
Taylor, G. M. J., Itani, T., Thomas, K. H., Rai, D., Jones, T., Windmeijer, F., Martin, R. M., Munafò, M. R., Davies, N. M., & Taylor, A. E. (2020) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntz072 · Cited by 68
Metadata
- Authors
- Molero, Y., Lichtenstein, P., Zetterqvist, J., Gumpert, C. H., & Fazel, S.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2015-06-02
- Volume
- 350
- Issue
- jun02 2
- Pages
- h2388-h2388
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W2114367427
- Cited by
- 54
- References
- 20
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.